CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.17) by 19.66 percent. This is a 60.83 percent increase over losses of $(2.40) per share from the same period last year. The company reported quarterly sales of $10.181 million which beat the analyst consensus estimate of $6.789 million by 49.96 percent. This is a 1.04K percent increase over sales of $892.000 thousand the same period last year.